



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Spirapril (hydrochloride)

Item No. 39278

CAS Registry No.: 94841-17-5
Formal Name: 7-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, monohydrochloride
Synonym: SCH 33844
MF: C₂₂H₃₀N₂O₅S₂ • HCl
FW: 503.1
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Spirapril (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the spirapril (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Spirapril (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of spirapril (hydrochloride) in these solvents is approximately 5, 10, and 25 mg/ml, respectively.

Description

Spirapril is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀ = 67 nM) and a prodrug form of spiraprilat.^{1,2} It inhibits the angiotensin I-induced pressor response in rats and dogs with half-maximal inhibitory dose (ID₅₀) values of 16 and 262 µg/kg, respectively.¹ Spirapril (5 mg/kg) decreases systolic blood pressure and left ventricular hypertrophy and induces angiogenesis in spontaneously hypertensive rats.² Formulations containing spirapril have previously been used in the treatment of hypertension and congestive heart failure.

References

1. Sybertz, E.J., Watkins, R.W., Ahn, H.S., *et al.* Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor. *J. Cardiovasc. Pharmacol.* **10 Suppl 7**, S105-108 (1987).
2. Olivetti, G., Cigola, E., Lagrasta, C., *et al.* Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. *J. Cardiovasc. Pharmacol.* **21(3)**, 362-370 (1993).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/20/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM